Article Page

Abstract

Orthodox quantum mechanics is a highly successful theory despite its serious conceptual flaws. It renounces realism, implies a kind of action-at-a-distance and is incompatible with determinism. Orthodox quantum mechanics states that Schrödinger’s equation (a deterministic law) governs spontaneous processes while measurement processes are ruled by probability laws. It is well established that time dependent perturbation theory must be used for solving problems involving time. In order to account for spontaneous processes, this last theory makes use of laws valid only when measurements are performed. This incoherence seems absent from the literature and may introduce innovative Orthodox Quantum Mechanics for the in silico KIF20A-derived Peptide agonistic drug molecules with mimicking sited and computer-aided designed properties on a poly-chemo-scaffold as an innovative drug-like scaffolds comprising potential clinical hyper-inhibitor properties in Patients With Advanced Pancreatic Cancer when combined with Gemcitabine.

Keywords

Success and Incoherence; Orthodox Quantum Mechanics; in silico; KIF20A-derived Peptide agonistic; drug molecules; mimicking sited; computer-aided designed on a poly-chemo-scaffold as an innovative drug-like scaffolds; clinical hyper-inhibitor; Advanced Pancreatic Cancer; when combined with Gemcitabine. Quantum Measurements―Time Dependent Perturbation Theory, Success and Incoherence; Orthodox Quantum Mechanics; in silico; KIF20A-derived Peptide; agonistic drug molecules; mimicking sited; computer-aided; poly-chemo-scaffold; innovative drug-like molecule; clinical hyper-inhibitor;

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) Success and Incoherence of Orthodox Quantum Mechanics in silico KIF20A-derived Peptide agonistic drug molecules mimicking sited and computer-aided designed on a poly-chemo-scaffold as an innovative drug-like scaffolds comprising potential clinical hyper-inhibitor properties in Patients With Advanced Pancreatic Cancer when combined with Gemcitabine.

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available